L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, and J. Lortet-tieulent, Global cancer statistics, 2012, Jemal, A. Global cancer statistics, pp.87-108, 2012.
DOI : 10.1002/ijc.29210

E. S. Nussbaum, H. R. Djalilian, K. H. Cho, and W. A. Hall, Brain metastases. Histology, multiplicity, surgery, and survival, Cancer Epidemiology of brain metastases. Cancer Radiother. 2015, vol.78, issue.19, pp.1781-1788, 1996.

S. Zimm, G. L. Wampler, D. Stablein, T. Hazra, and H. Young, Intracerebral metastases in solid-tumor patients: Natural history and results of treatment, Cancer, vol.80, issue.2, pp.384-394, 1981.
DOI : 10.1002/1097-0142(19810715)48:2<384::AID-CNCR2820480227>3.0.CO;2-8

Y. K. Won, J. Y. Lee, Y. N. Kang, J. S. Jang, J. Kang et al., Stereotactic radiosurgery for brain metastasis in non-small cell lung cancer, Radiation Oncology Journal, vol.33, issue.3, pp.207-216, 2015.
DOI : 10.3857/roj.2015.33.3.207

B. Besse, S. Le-moulec, J. Mazières, H. Senellart, F. Barlesi et al., Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study Hallmarks of cancer: The next generation, Clin. Cancer Res. Cell, vol.2015, issue.144, pp.1896-1903, 2011.

R. Rosell, E. Carcereny, R. Gervais, A. Vergnenegre, B. Massuti et al., Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, The Lancet Oncology, vol.13, issue.3, pp.239-246, 2012.
DOI : 10.1016/S1470-2045(11)70393-X

B. Margono and Y. Ichinose, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N. Engl. J. Med, vol.361, pp.947-957, 2009.

L. V. Sequist, J. C. Yang, -. Yamamoto, N. O-'byrne, K. Hirsh et al., Mutations, Journal of Clinical Oncology, vol.31, issue.27, pp.31-3327, 2013.
DOI : 10.1200/JCO.2012.44.2806

A. T. Shaw, D. Kim, K. Nakagawa, T. Seto, L. Crinó et al., -Positive Lung Cancer, New England Journal of Medicine, vol.368, issue.25, pp.2385-2394, 2013.
DOI : 10.1056/NEJMoa1214886

URL : https://hal.archives-ouvertes.fr/in2p3-00451031

D. B. Costa, A. T. Shaw, S. I. Ou, B. J. Solomon, G. J. Riely et al., -Rearranged Non???Small-Cell Lung Cancer and Brain Metastases, Journal of Clinical Oncology, vol.33, issue.17, pp.1881-1888, 2015.
DOI : 10.1200/JCO.2014.59.0539

URL : https://hal.archives-ouvertes.fr/in2p3-00451031

M. Schuler, Y. Wu, V. Hirsh, K. O-'byrne, N. Yamamoto et al., First-Line Afatinib versus Chemotherapy in Patients with Non???Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases, Journal of Thoracic Oncology, vol.11, issue.3, pp.380-390, 2016.
DOI : 10.1016/j.jtho.2015.11.014

L. Crinò, M. Ahn, F. Marinis, H. J. Groen, H. Wakelee et al., -Rearranged Non???Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2, Journal of Clinical Oncology, vol.34, issue.24, pp.2866-2873, 2016.
DOI : 10.1200/JCO.2015.65.5936

J. F. Deeken and W. Löscher, The Blood-Brain Barrier and Cancer: Transporters, Treatment, and Trojan Horses, Clinical Cancer Research, vol.13, issue.6, pp.1663-1674, 2007.
DOI : 10.1158/1078-0432.CCR-06-2854

J. K. Wrobel and M. Toborek, Blood???brain Barrier Remodeling during Brain Metastasis Formation, Molecular Medicine, vol.22, issue.1, pp.32-40, 2016.
DOI : 10.2119/molmed.2015.00207

P. Dartevelle, E. Taranchon, and B. Besse, Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites, J. Thorac. Oncol, vol.4, pp.1212-1220, 2009.

M. Hanibuchi, S. Kim, I. J. Fidler, and Y. Nishioka, The molecular biology of lung cancer brain metastasis: an overview of current comprehensions and future perspectives, The Journal of Medical Investigation, vol.61, issue.3.4, pp.241-253
DOI : 10.2152/jmi.61.241

A. Meert and S. Noel, The role of RAS oncogene in survival of patients with lung cancer: A systematic review of the literature with meta-analysis, Br. J. Cancer, vol.92, pp.131-139, 2005.

N. Guibert, M. Ilie, E. Long, V. Hofman, L. Bouhlel et al., KRAS Mutations in Lung Adenocarcinoma: Molecular and Epidemiological Characteristics, Methods for Detection, and Therapeutic Strategy Perspectives, Current Molecular Medicine, vol.15, issue.5, pp.418-432, 2015.
DOI : 10.2174/1566524015666150505161412

R. Ramlau, T. Cufer, P. Berzinec, R. Dziadziuszko, W. Olszewski et al., Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe, Journal of Thoracic Oncology, vol.10, issue.9, pp.1370-1374, 2015.
DOI : 10.1097/JTO.0000000000000621

D. Shin, I. I. Na, C. H. Kim, S. Park, H. Baek et al., EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas, Journal of Thoracic Oncology, vol.9, issue.2, pp.195-199
DOI : 10.1097/JTO.0000000000000069

J. Guan, M. Chen, N. Xiao, L. Li, Y. Zhang et al., EGFR mutations are associated with higher incidence of distant metastases and smaller tumor size in patients with non-small-cell lung cancer based on PET/CT scan, Medical Oncology, vol.1, issue.5, 2016.
DOI : 10.1007/s12032-015-0714-8

M. Y. Baek, H. K. Ahn, K. R. Park, H. Park, S. M. Kang et al., Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer, The Korean Journal of Internal Medicine, p.20, 2016.
DOI : 10.3904/kjim.2015.158

S. Renaud, J. Seitlinger, P. Falcoz, M. Schaeffer, A. Voegeli et al., Specific KRAS amino acid substitutions and EGFR mutations predict site-specific recurrence and metastasis following non-small-cell lung cancer surgery, British Journal of Cancer, vol.7, issue.3, pp.346-353, 2016.
DOI : 10.1371/journal.pone.0106053

L. E. Hendriks, E. F. Smit, B. A. Vosse, W. W. Mellema, D. A. Heideman et al., EGFR mutated non-small cell lung cancer patients: More prone to development of bone and brain metastases?, Lung Cancer, vol.84, issue.1, pp.86-91, 2014.
DOI : 10.1016/j.lungcan.2014.01.006

B. T. Li, E. Lou, M. Hsu, H. A. Yu, J. Naidoo et al., Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers, PLOS ONE, vol.14, issue.19, 2016.
DOI : 10.1371/journal.pone.0146063.t004

B. Li, S. Sun, M. Yang, J. Shi, W. Xu et al., The correlation between EGFR mutation status and the risk of brain metastasis in patients with lung adenocarcinoma, Journal of Neuro-Oncology, vol.82, issue.2, pp.79-85, 2015.
DOI : 10.1007/s11060-015-1776-3

S. Rossi, E. Argento, M. Basso, A. Strippoli, V. Dadduzio et al., Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis, Molecular Diagnosis & Therapy, vol.14, issue.16, pp.55-63, 2016.
DOI : 10.1007/s40291-015-0176-x

S. M. Shin, B. T. Cooper, A. Chachoua, J. Butler, B. Donahue et al., Survival but not brain metastasis response relates to lung cancer mutation status after radiosurgery, Journal of Neuro-Oncology, vol.77, issue.3, pp.483-491, 2016.
DOI : 10.1007/s11060-015-1986-8

H. Li, X. Zhang, J. Cao, P. Su, J. Lian et al., Exon 19 deletion of epidermal growth factor receptor is associated with prolonged survival in brain metastases from non-small-cell lung cancer, Tumor Biology, vol.15, issue.15, pp.9251-9258, 2015.
DOI : 10.1007/s13277-015-3653-2

S. Singh, J. Trevino, N. Bora-singhal, D. Coppola, E. Haura et al., EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer, Molecular Cancer, vol.11, issue.1, p.73, 2012.
DOI : 10.1038/sj.bjc.6690178

G. L. Lopes, E. F. Vattimo, and G. D. Junior, Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer, Jornal Brasileiro de Pneumologia, vol.41, issue.4, pp.365-375, 2015.
DOI : 10.1590/S1806-37132015000004531

S. Wang and Z. Wang, Meta-analysis of Epidermal Growth Factor Receptor and KRAS Gene Status between Primary and Corresponding Metastatic Tumours of Non-small Cell Lung Cancer, Clinical Oncology, vol.27, issue.1, pp.30-39, 2015.
DOI : 10.1016/j.clon.2014.09.014

P. Ballard, J. W. Yates, Z. Yang, D. Kim, J. C. Yang et al., Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity, Clinical Cancer Research, vol.22, issue.20, pp.5130-5140, 2016.
DOI : 10.1158/1078-0432.CCR-16-0399

G. Toyokawa, T. Seto, M. Takenoyama, and Y. Ichinose, Insights into brain metastasis in patients with ALK + lung cancer: Is the brain truly a sanctuary? Cancer Metastasis Rev, pp.797-805, 2015.

P. Goldstraw, J. Crowley, K. Chansky, D. J. Giroux, P. A. Groome et al., The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours, Journal of Thoracic Oncology, vol.2, issue.8, pp.706-714, 2007.
DOI : 10.1097/JTO.0b013e31812f3c1a

E. A. Eisenhauer, P. Therasse, J. Bogaerts, L. H. Schwartz, D. Sargent et al., New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, vol.45, issue.2, pp.228-247, 2009.
DOI : 10.1016/j.ejca.2008.10.026

W. Jacot, E. Lopez-crapez, S. Thezenas, R. Senal, F. Fina et al., Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles, Breast Cancer Research, vol.17, issue.6, p.133, 2011.
DOI : 10.1158/1078-0432.CCR-10-2185

G. A. Masters, S. Temin, C. G. Azzoli, G. Giaccone, S. Baker et al., Systemic Therapy for Stage IV Non???Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update, Journal of Clinical Oncology, vol.33, issue.30, pp.3488-3515, 2015.
DOI : 10.1200/JCO.2015.62.1342

M. Reck, S. Popat, N. Reinmuth, D. De-ruysscher, K. M. Kerr et al., Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.25, issue.suppl 3, pp.27-39, 2014.
DOI : 10.1093/annonc/mdu199

R. Soffietti, P. Cornu, J. Y. Delattre, R. Grant, F. Graus et al., EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force, European Journal of Neurology, vol.6, issue.7, pp.674-681, 2006.
DOI : 10.1093/annonc/mdh276

L. Rhun, É. Dhermain, F. Noël, G. Reyns, N. Carpentier et al., Recommandations de l???Anocef pour la prise en charge des m??tastases c??r??brales, Cancer/Radioth??rapie, vol.19, issue.1, pp.66-71
DOI : 10.1016/j.canrad.2014.11.006